Differentiation of ovarian serous carcinoma from ovarian clear cell carcinoma using a 10-gene signature selected by comprehensive gene expression analysis
FUKUSHIMA JOURNAL OF MEDICAL SCIENCE · 2024
DOI: 10.5387/fms.23-00011 ↗Kurz gefasst
Fachartikel in der Zeitschrift FUKUSHIMA JOURNAL OF MEDICAL SCIENCE, 2024. Verfasst von Shinji Nomura und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, Fukushima Medical University. Hauptthemen laut MEDLINE: Ovarian Neoplasms, Adenocarcinoma, Clear Cell, Cystadenocarcinoma, Serous. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
AIM: Ovarian serous carcinoma (OSC) and ovarian clear cell carcinoma (OCCC) are two major histological types of epithelial ovarian carcinoma (EOC), each with different biological features and clinical behaviors. Although immunostaining is commonly used for differential diagnosis between OSC and OCCC, correct identification of EOC with mixed-type histology is sometimes a diagnostic challenge. The aim of the present study was to explore candidate genes as potential diagnostic biomarkers that distinguish OSC from OCCC. METHODS: A total of 57 surgical specimens were obtained from EOC patients who had previously undergone primary debulking surgery. Total RNAs were extracted from fresh-frozen tissues of EOC patients, and were used for comprehensive gene expression analysis using DNA microarray technology. RESULTS: Ten candidate genes, FXYD2, TMEM101, GABARAPL1, ARG2, GLRX, RBPMS, GDF15, PPP1R3B, TOB1, and GSTM3 were up-regulated in OCCC compared to OSC. All EOC patients were divided into two groups according to hierarchical clustering using a 10-gene signature. CONCLUSION: Our data suggest that the 10 candidate genes would be an excellent marker for distinguishing OSC from OCCC. Furthermore, the molecular signatures of the 10 genes may enlighten us on the differences in carcinogenesis, and provide a theoretical basis for OCCC's resistance to chemotherapy in the future.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Obstetrics and Gynecology, Fukushima Medical University.
- Nippon Gene Co., Ltd.
- Medicrome Inc.
- Translational Research Center, Fukushima Medical University.
- Department of Diagnostic Pathology, Fukushima Medical University.
Zitieren
APA
Nomura, S., Watanabe, T., Honma, R., Matsukura, S., Ito, E., Imai, J. I., Kiko, Y., Suzuki, O., Hashimoto, Y., Kojima, M., Furukawa, S., Soeda, S., Watanabe, S., & Fujimori, K. (2024). Differentiation of ovarian serous carcinoma from ovarian clear cell carcinoma using a 10-gene signature selected by comprehensive gene expression analysis. FUKUSHIMA JOURNAL OF MEDICAL SCIENCE. https://doi.org/10.5387/fms.23-00011
Vancouver
Nomura S, Watanabe T, Honma R, Matsukura S, Ito E, Imai JI, et al. Differentiation of ovarian serous carcinoma from ovarian clear cell carcinoma using a 10-gene signature selected by comprehensive gene expression analysis. FUKUSHIMA JOURNAL OF MEDICAL SCIENCE. 2024. doi:10.5387/fms.23-00011
BibTeX
@article{Nomura2024,
author = {Nomura, Shinji and Watanabe, Takafumi and Honma, Reiko and Matsukura, Susumu and Ito, Emi and Imai, Jun-Ichi and Kiko, Yuichiro and Suzuki, Osamu and Hashimoto, Yuko and Kojima, Manabu and Furukawa, Shigenori and Soeda, Shu and Watanabe, Shinya and Fujimori, Keiya},
title = {Differentiation of ovarian serous carcinoma from ovarian clear cell carcinoma using a 10-gene signature selected by comprehensive gene expression analysis},
journal = {FUKUSHIMA JOURNAL OF MEDICAL SCIENCE},
year = {2024},
doi = {10.5387/fms.23-00011}
}
EUVIMED